肝硬化患者体外膜氧合支持结局:全国人群队列研究
该研究利用台湾全民健康保险数据库回顾性分析2000至2013年接受ECMO支持的7003例患者,其中233例(3.3%)合并肝硬化。肝硬化患者院内死亡风险显著高于非肝硬化组(76.4% vs 60.7%;OR 1.97;95%CI 1.44-2.70),且并发症风险更高。研究提示对肝硬化患者使用ECMO需谨慎并严格筛选。
要点
- 肝硬化患者ECMO院内死亡风险显著高于非肝硬化组(76.4% vs 60.7%;OR 1.97)。
- 肝硬化组新发透析和大规模输血(>10单位红细胞)等并发症风险更高。
- 年龄≥65岁、呼吸系统疾病、低白蛋白血症及肝移植患者院内和1年死亡率更高。
核心结论
- 肝硬化患者接受ECMO支持的院内死亡风险显著高于非肝硬化患者。
- 研究结果对肝硬化患者使用ECMO的效用提出质疑,尤其当存在2个以上危险因素时。
- 对肝硬化患者使用ECMO应谨慎并严格筛选患者。
研究设计与样本
- 基于台湾全民健康保险数据库的回顾性队列研究。
- 共分析7003例接受ECMO的患者,其中233例(3.3%)合并肝硬化。
主要发现
- 肝硬化组院内死亡率为76.4%,非肝硬化组为60.7%(OR 1.97;95%CI 1.44-2.70)。
- 肝硬化组新发透析和大规模输血(>10单位红细胞)等并发症风险更高。
- 年龄≥65岁、呼吸系统疾病、低白蛋白血症及肝移植患者院内和1年死亡率更高。
- 存在2个或以上危险因素的患者死亡率分别为90.3%和95.8%。
- 肝硬化与随访期间全因死亡率和肝脏相关结局发生率更高相关。
临床怎么用
- 对肝硬化患者启动ECMO前应评估危险因素,尤其注意年龄≥65岁、呼吸系统疾病、低白蛋白血症及肝移植状态。
- 存在2个以上危险因素时,ECMO的效用存疑,需谨慎决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Extracorporeal membrane oxygenation (ECMO) is used for life support in patients with liver cirrhosis (LC). However, there have been no studies evaluating the outcome of ECMO support in patients with LC. METHODS: Using Taiwan's National Health Insurance (NHI) database, we retrospectively evaluated patients with LC who received veno-venous or veno-arterial ECMO between 1 January 2000 and 31 December 2013. The outcomes included ECMO-related complications, in-hospital mortality, all-cause mortality and long-term outcomes in patients with and without LC. RESULTS: A total of 7003 patients who received ECMO, of whom 233 (3.3%) had LC, were eligible for analysis. The LC patients who received ECMO support had a significantly higher risk of in-hospital mortality than the non-LC group (76.4% vs 60.7%; odds ratio 1.97; 95% confidence interval 1.44-2.70). The LC group also had a higher risk of complications, including de novo dialysis and massive blood transfusion with >10 units of red blood cells. Patients ≥65 years of age, patients with respiratory disease, patients with hypoalbuminaemia and liver transplant patients had higher in-hospital and 1-year mortality. The mortality rates for patients with 2 or more risk factors were 90.3% and 95.8%, respectively. LC was associated with a higher incidence of all-cause mortality and liver-related outcomes during follow-up. CONCLUSIONS: Our findings raise questions regarding the utility of ECMO for LC patients, especially when >2 risk factors have been identified. ECMO support for LC patients should be used with caution and with careful patient selection.
引用
- Chou AH, Wu VC, Chen DY, et al. Outcome of extracorporeal membrane oxygenation support in patients with liver cirrhosis: a nationwide population-based cohort study. Eur J Cardiothorac Surg. 2020. PMID: 32282923. doi:10.1093/ejcts/ezaa089
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。